WeDaita

WeDaita | AI Drug Discovery Platform

BioMedAI From Target to Candidate — in One Platform

An end-to-end AI platform for drug discovery researchers. Identify novel targets, design protein & antibody therapeutics, and accelerate small molecule optimisation — all within a single intelligent workflow.

90%

Reduced Research Time

70%

Drug Design Cycle

2×

Clinical Trial Excution

Try BioMedAI See It in Action Book a Call

Drug Discovery Is Broken at Scale

Researchers waste years on literature, fragmented tools, and manual hypothesis generation — before a single molecule is designed.

12+

Years per Drug

Average time from target identification to approval — most lost to slow early-stage research.

$2.5B

Average R&D Cost

The cost of bringing a single drug to market, compounded by high failure rates in early discovery.

90%

Failure Rate

Of drug candidates fail in clinical trials — many due to poor target validation in discovery.

BioMedAI Platform

One Platform. Full Discovery Pipeline.

Three agent modules that cover the complete drug discovery workflow — from target to candidate.

Live Now

Stage 1 · Research

DBRA

Deep Biomedical Research Agents

Solves the Haystack Problem — automating evidence synthesis to generate and validate novel drug targets — in hours, not months.

Deep Research on drug research
Disease-to-target hypothesis generation
Drug Target Prioritization
Drug Repurposing

90%

Reduced Research Time

In Development

Stage 2 · Design

ADDA

Autonomous Drug Design Agents

Bridges the Translation Gap — automating biologic and small molecule drug design to reduce preclinical failure rates.

Protein / antibody drug design
Peptide/Macrocycle
Small molecule design & optimisation In Dev

70%

Faster Drug Design Cycles

Coming Soon

Stage 3 · Translation

CTIA

Clinical Trial Intelligence Agents

Addresses Late-Stage Attrition — AI-assisted protocol design, predictive recruitment, and portfolio optimization.

Digital twin trial simulation
Predictive patient recruitment
AI-assisted protocol design
Portfolio optimization

2×

Faster Clinical Trial Execution

See BioMedAI in Action

See how BioMedAI DBRA agents deliver trusted biomedical insights through intelligent AI agents

Plug-and-play biomedical AI via WeDaita MCP services
High-confidence insights from verified medical and clinical databases
Rapid literature review and clinical trial intelligence
Seamless agent-tool integration with zero local installation

Grounded in Primary Scientific Sources

Every insight traces back to PubMed, UniProt, ChEMBL, PDB, and 7+ other primary databases — not black-box outputs.

Built by Drug Discovery Scientists

Our team has decades of combined experience in computational biology, medicinal chemistry, and AI research.

Researcher in the Loop, Always

BioMedAI accelerates your thinking — your scientific judgement drives every key decision.

What Will You Work On Today?

Choose Your Discovery Workflow

BioMedAI adapts to where you are in the pipeline. Start from any stage.

DBRA · Live

I need to find novel drug targets for a disease area

DBRA agents search 11+ databases in parallel — PubMed, UniProt, OMIM, DisGeNET and more — delivering a ranked, evidence-backed target list in hours.

Try DBRA

ADDA · Live

I need to design a protein or antibody therapeutic

ADDA's protein and antibody design agents generate, score, and optimise therapeutic candidates — including affinity maturation and developability assessment.

Try ADDA

ADDA · In Development

I need to optimise a small molecule hit series

ADDA's small molecule module will generate ADMET-aware analogues and scaffold hops from your initial hit — generative chemistry with property guardrails.

Get Notified

CTIA · Coming Soon

I need to translate a candidate into a clinical plan

CTIA will assist with protocol design, biomarker strategy, and regulatory pathway intelligence — bridging preclinical findings to first-in-human readiness.

Get Notified